SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
1-Year Return
23.25%
This Quarter Return
+18.4%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$461M
AUM Growth
+$72.1M
(+19%)
Cap. Flow
+$45.8M
Cap. Flow
% of AUM
9.93%
Top 10 Holdings %
Top 10 Hldgs %
97.75%
Holding
13
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$45.8M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$4.03B
| $155M | 33.49% |
2,346,630
| – | – |
|
2
ARS Pharmaceuticals
SPRY
$995M
| $70M | 15.18% |
4,012,903
| – | – |
|
3
CRISPR Therapeutics
CRSP
$4.99B
| $51M | 11.06% |
1,048,951
| – | – |
|
|
ZBIO
4
Zenas BioPharma, Inc. Common Stock
ZBIO
$864M
| $47.6M | 10.32% |
4,911,539
| – | – |
|
|
5
Oric Pharmaceuticals
ORIC
$1.06B
| $45.8M | 9.93% |
+4,514,929
| New | +$45.8M |
|
6
Mineralys Therapeutics
MLYS
$2.7B
| $42.3M | 9.17% |
3,127,933
| – | – |
|
7
Design Therapeutics
DSGN
$367M
| $22M | 4.77% |
6,526,476
| – | – |
|
8
Oculis Holding
OCS
$901M
| $6.26M | 1.36% |
322,500
| – | – |
|
|
ALMS
9
Alumis Inc. Common Stock
ALMS
$469M
| $5.88M | 1.27% |
1,959,896
| – | – |
|
10
Nkarta
NKTX
$161M
| $5.53M | 1.2% |
3,333,333
| – | – |
|
|
ORKA
11
Oruka Therapeutics, Inc. Common Stock
ORKA
$612M
| $4.82M | 1.05% |
430,330
| – | – |
|
12
KALA BIO
KALA
$102M
| $2.85M | 0.62% |
598,940
| – | – |
|
13
enGene Holdings
ENGN
$265M
| $2.72M | 0.59% |
747,750
| – | – |
|